Skip to main content

Local Immunomodulation around implants by innovative auxiliary hydrogel-based systems encapsulating autologous and phenotype controlled macrophages

Objective

IMMODGEL aims to identify adverse immune reactions to dental and larynx titanium implants and to develop a novel therapeutic strategy to significantly decrease the implant and medical device failure caused by these reactions via design of an innovative immunomodulatory system. The system will be designed to be fixed to an implant via an adhesive polyelectrolyte multilayer and control the immune response by autologous, phenotype modulated macrophages encapsulated in a hydrogel. The auxiliary nature of the design allows it to be adjusted to any implant, medical device or transplant. IMMODGEL will apply complex systems immunology, epidemiology, and functional approaches to identify key adverse immune reactions caused by implants and detrimental macrophage phenotypes around titanium implants. This will be used to establish the optimal biomaterial composition and cytokine delivery system for the immunomodulatory hydrogel design to revert macrophage-induced inflammatory reactions (M1) to the optimal tolerogenic and healing reactions (M2). Long-term fixation of the desired M2 phenotype will significantly decrease the level and duration of implant-induced inflammation, and optimise healing phase. The interaction of implants and medical devices with the immune system will be modelled to develop a “Foreign Body Response on-a-chip” to predict patient’s specific responses to implant materials and modify the immunomodulatory hydrogel accordingly, as a step towards personalized implants with minimal adverse reactions. The gels will be incorporated to engineered tissues for validation. Validation of the approach will be performed in vivo in animal models. Significantly suppressed inflammatory responses and optimal tissue remodelling and healing around titanium implants is expected. The key innovation will be the development of IMMODGEL as an auxiliary system to improve the outcomes of implantation and reduce the cost of implant complication and related medical costs in Europe.

Field of science

  • /natural sciences/chemical sciences/inorganic chemistry/inorganic compounds
  • /medical and health sciences/basic medicine/immunology
  • /medical and health sciences/health sciences/epidemiology
  • /medical and health sciences/medical biotechnology/medical bioproducts/implants

Call for proposal

FP7-HEALTH-2013-INNOVATION-1
See other projects for this call

Funding Scheme

CP-FP - Small or medium-scale focused research project
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

STEINBEIS 2I GMBH
Address
Kienestrasse 35
70174 Stuttgart
Germany
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Mercedes Dragovits (Dr.)

Participants (9)

UNIVERSITE DE STRASBOURG
France
EU contribution
€ 831 078,40
Address
Rue Blaise Pascal 4
67081 Strasbourg
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Sandrine Schott-Carrière (Mrs.)
RUPRECHT-KARLS-UNIVERSITAET HEIDELBERG
Germany
EU contribution
€ 969 461
Address
Seminarstrasse 2
69117 Heidelberg
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Julia Kzhyshkowska (Prof.)
THE UNIVERSITY OF NOTTINGHAM
United Kingdom
EU contribution
€ 675 914,40
Address
University Park
NG7 2RD Nottingham
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Jill Harris (Mrs.)
THE BRIGHAM AND WOMEN'S HOSPITAL INC
United States
EU contribution
€ 581 269,50
Address
Francis Street 75
02241 Boston Ma
Activity type
Research Organisations
Administrative Contact
Ali Khademhosseini (Prof.)
PROTIP MEDICAL
France
EU contribution
€ 1 109 353,20
Address
8 Place De L'hopital
67000 Strasbourg
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Nihal Engin Vrana (Dr.)
PROTOBIOS OU
Estonia
EU contribution
€ 653 464,50
Address
Maealuse 4
12618 Tallinn
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Kaia Palm (Dr.)
CONTIPRO BIOTECH SRO

Participation ended

Czechia
EU contribution
€ 306 231,50
Address
Dolni Dobrouc 401
56102 Dolni Dobrouc
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Leona Markova (Ms.)
CONTIPRO AS
Czechia
EU contribution
€ 219 411,60
Address
Dolni Dobrouc 401
561 02 Dolni Dobrouc
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Leona Markova (Ms.)
STEINBEIS INNOVATION GGMBH

Participation ended

Germany
EU contribution
€ 505 132
Address
Willi Bleicher Strasse 19
70174 Stuttgart
Activity type
Research Organisations
Administrative Contact
Mercedes Laura Dragovits (Dr.)